About 20 results found for searched term "GPR" (0.058 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M5292 | GPR120-IN-1 | GPR/FFAR |
| GPR120-IN-1 is a selective Gpr120 agonist with a logEC50 of 7.62. | ||
| M6150 | GPR39-C3 | GPR/FFAR |
| TC-G-1008 | ||
| GPR39-C3 is a potent and orally available GPR39 agonist with EC50 values of 0.4 and 0.8 nM for rat and human receptors respectively. | ||
| M8246 | GPR35 Agonist, Compound 10 | Others |
| GPR35 agonist Compound 10 is a GPR35 agonist the binds with higher affinity than other known agonists, such as kynurenic acid and zaprinast. | ||
| M10562 | GPR81 agonist 1 | GPR/FFAR |
| GPR81 agonist I | ||
| GPR81 agonist 1 is a potent and highly selective GPR81 agonist, with EC50 values of 58 nM and 50 nM for human and mouse GPR81, respectively. | ||
| M14813 | GPRP acetate | Peptides |
| Gly-Pro-Arg-Pro acetate; Pefa 6003 acetate | ||
| GPRP acetate (Gly-Pro-Arg-Pro acetate) is a fibrin polymerization inhibitor that inhibits the interaction of fibrinogen with the platelet membrane glycoprotein IIb/IIIa complex (GPIIb/IIIa). | ||
| M28005 | GPR120 Agonist 2 | GPR/FFAR |
| GPR120 Agonist 2 is a GPR120 agonist extracted from patent US 20110313003 A1, example 209. | ||
| M28020 | GPR52 antagonist-1 | Others |
| GPR52 antagonist-1 (Compound 43) is a GPR52 antagonist with an IC50 of 0.63 μM. GPR52 antagonist-1 reduces mHTT (mutant huntingtin protein) levels by targeting GPR52 and promotes survival of mouse primary striatal neurons. | ||
| M29158 | Tos-Gly-Pro-Arg-ANBA-IPA acetate | Others |
| tos-GPR-ANBA-IPA acetate | ||
| Tos-Gly-Pro-Arg-ANBA-IPA (tos-GPR-ANBA-IPA) acetate is a chromogenic peptide substrate. Tos-Gly-Pro-Arg-ANBA-IPA acetate can be used for luminescence measurement. | ||
| M29237 | GPR40 agonist 4 | GPR/FFAR |
| GPR40 agonist 4 is a potent free fatty acid receptor 1 (FFA1/ GPR40) agonist with a pEC50 of 7.54. | ||
| M30472 | GPRP | Integrin |
| Gly-Pro-Arg-Pro; Pefa 6003 | ||
| GPRP (Pefa 6003) is a fibrin polymerization inhibitor that inhibits the interaction of fibrinogen with the platelet membrane glycoprotein IIb/IIIa complex (GPIIb/IIIa). | ||
| M30771 | GPR35 agonist 4 | GPR/FFAR |
| GPR35 agonist 4 (compound 10) is a potent GPR35 agonist with an pEC50 of 5.86. GPR35 agonist 4 shows high potency human and rat GPR35. Mutation of arginine 3.36 eliminates agonist function of GPR35 agonist 4. | ||
| M30994 | Tos-Gly-Pro-Arg-ANBA-IPA | Others |
| tos-GPR-ANBA-IPA | ||
| Tos-Gly-Pro-Arg-ANBA-IPA is a chromogenic peptide substrate. Tos-Gly-Pro-Arg-ANBA-IPA can be used for luminescence measurement. | ||
| M41841 | GPR119 agonist 2 | GPR/FFAR |
| GPR119 agonist 2 is an orally active GPR119 agonist. | ||
| M42920 | GPR52 receptor modulator 1 | Others |
| GPR52 receptor modulator 1 (Procedure 1) is a GPR52 receptor modulator with the potential to study neuropsychiatric diseases. | ||
| M50188 | MrgprX2 antagonist-1 | MRGPR |
| MrgprX2 antagonist-1 is an antagonist of MrgprX2 that can be used in studies related to inflammatory skin diseases. | ||
| M50190 | MrgprX2 antagonist-8 | MRGPR |
| MrgprX2 antagonist-8 is a MrgprX2 antagonist for studies related to inflammatory diseases. | ||
| M50191 | MRGPRX1 agonist 1 | MRGPR |
| MRGPRX1 agonist 1 is a potent Mas-related G protein-coupled receptor X1 (MRGPRX1) agonist with an EC50 value of 50 nM and is inactive against MRGPRC11. | ||
| M50193 | MRGPRX4 modulator-1 | MRGPR |
| MRGPRX4 modulator-1 is a potent MAS-associated G-protein receptor X4 (MRGPRX4) modulator with antagonistic activity against MRGPR4 and an IC50 < 100 nM.MRGPRX4 modulator-1 can be used in studies related to MRGPRX4-dependent disorders, such as itch, pain, and autoimmune diseases. | ||
| M50194 | MRGPRX4 modulator-2 | MRGPR |
| MRGPRX4 modulator-2 is a potent MRGPR X4 modulator with antagonistic activity against MRGPRX4 and an IC50 < 100 nM.MRGPRX4 modulator-2 can be used in studies related to autoimmune diseases. | ||
| M53374 | GPR | Caspase |
| GPR is a three amino acid peptide. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
